Curevo Vaccine Announces Positive Topline Results from

-- Positive data from 876-patient head-to-head trial versus Shingrix® shows amezosvatein met the primary immunogenicity endpoint, eliciting a robust immune...

Related Keywords

United States ,China ,William Smith ,George Simeon ,Alliance For Multispecialty Research ,Vaccine Response Rate ,Guy De La Rosa ,Chief Medical ,Multispecialty Research ,Chief Executive Officer ,Like Shingrix ,Curevo Vaccine ,Pm24 ,Shingles ,Herpes Zoster ,Vaccine ,